Table 3 Baseline characteristics of patients and sampling (CA19–9 – carcinoma antigen 19–9; CgA – chromogranin A; LMWH – low molecular weight heparin; PAI – platelet aggregation inhibitors)
Patients (N = 89) | Sampling (N = 92) | ||
|---|---|---|---|
Male/female | 38/51 | Examiners: Z.Sz/L.Cz | 70/22 |
Age (year) | 66.1 (27–95; median: 69) | Punctures per examination | 4 (3–7; median: 4) |
Tumor location | 3 2 punctures 4 punctures 5 punctures 6 punctures 7 punctures | 23 (25%) 47 (51.1%) 17 (18.5%) 6 (4.3%) 1 (1.1%) | |
Head Body Tail Diffuse | 71 (79.8%) 7 (7.9%) 8 (8.9%) 3 (3.4%) | ||
Tumor size (mm) | 31.8 (7–62; median: 30) | LMWH PAI | 10 (10.9%) 14 (15.2%) |
CA 19–9 | |||
Elevated Normal No data CgA elevation | 44 (47.2%) 27 (29.3%) 18 (19.5%) 5 (5.6%) | Needle type Echotip EZ Shot 2 | 37 (40.2%) 55 (59.8%) |